Vice Article: Psychedelics Patent Claim Raises Questions From Researchers Who Say They Did It First

Vice report

A recent application from CB Therapeutics on biosynthetic psilocybin is emblematic of the IP concerns around novelty and obviousness the psychedelic field will face.

Two weeks ago, German microbiologist Felix Blei received a barrage of messages, all telling him to look up a patent application filed by CB Therapeutics, a psychedelics company.

The application, published on May 20, was originally filed on November 15, 2019. (Patent applications are kept secret for 18 months.) First reported by Psilocybin Alpha, the application has claims on organisms genetically modified to produce psilocybin by giving them the genes for enzymes that make the compound naturally in mushrooms.

Read more at 

https://www.vice.com/en/article/qj8vmp/psychedelics-patent-claim-raises-questions-from-researchers-who-say-they-did-it-first?utm_campaign=6%2F4%20Editorial%20Newsletter%20%28SJfRDq%29&utm_medium=email&utm_source=Everyone%20minus%20suppressed&_ke=eyJrbF9jb21wYW55X2lkIjogIldMenJSQyIsICJrbF9lbWFpbCI6ICJob2NraW5nLnNlYW5AZ21haWwuY29tIn0%3D

Cannabis Law Report Has Been Publishing Legal, Professional & Regulated
Cannabis News Daily Since 2016 – All For Free

We want to carry on providing the important cannabis sector
news for free for all our readers.

Costs are rising to produce Cannabis Law Report and we’d like to ask you,
our readers, for a small donation.


Primary Sponsor

New: Free USA Cannabis Case Law Search – New Cases Daily

Directory Categories

Sponsor – aBizinaBox

Top Marijuana Blog
%d bloggers like this: